Business Wire

Mundipharma Strengthens Position as a Leader in Biosimilars with Acquisition of Development Company Cinfa Biotech

Jaa

The Mundipharma global network of independent associated companies has today added development capabilities to its biosimilars platform with the purchase of biosimilars development company Cinfa Biotech.

The announcement sees the Mundipharma network (including NAPP Pharmaceuticals in the UK) gain immediate access to Pelmeg® (B12019), a biosimilar to Neulasta® (pegfilgrastim), which received CHMP recommendation for approval on 20th September 2018.

Alberto Martinez, President and CEO, Mundipharma International Ltd, “Our biosimilars platform is a key component of our growth strategy and today’s acquisition is the obvious next step in us ensuring we remain agile and innovative in the biosimilars space.

“We have successfully demonstrated our commercial excellence in biosimilars by building a market leading platform. Through our partnership with Celltrion on Remsima ® and Truxima ® we estimate savings for healthcare systems of approximately €330m 2 from launch to the end of 2017. By acquiring Cinfa Biotech we have now taken the first step in our plans to, not only expand our biosimilars footprint, but to develop future biosimilars which will continue to afford healthcare systems further savings and, in some cases, wider access for patients.”

Pelmeg® (originator Neulasta®3) is a pegylated version of granulocyte-colony stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia that works by stimulating the bone marrow to produce more neutrophils, thereby reducing the incidence of infection.

With a non-US market worth of $603mllion1 and originator patents already expired, pegfilgrastim biosimilars offer an exciting market opportunity.

Enrique Ordieres, President of Infarco the parent company of Cinfa Group, commented, “After having successfully developed and manufactured our first biosimilar, we strongly believe Mundipharma is best placed to take Pelmeg ® forward through the Cinfa Biotech acquisition. They have the pedigree and proven track record of launching biosimilars in Europe, have built strong partnerships with payers, hospital specialists and decision makers and have the deep local understanding of complex tender environments.”

-Ends-

Notes to editors:

About the Mundipharma network

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.

For more information please visit: www.mundipharma.com.

About Cinfa Biotech

Cinfa Biotech was created in 2013 as part of the Spanish Cinfa Group. The company conduct biosimilars development and manufacturing exclusively in Europe. Highest European quality standards based on strict guidelines and their specialist know-how are the key to their success in the global biosimilars market.

They currently have two product candidates in development including: Cinfa Biotech’s lead product candidate, pegfilgrastim, a biosimilar version of Neulasta® (INN: pegfilgrastim) to treat chemotherapy-induced neutropenia. Pegfilgrastim, a granulocyte colony-stimulating factor (G-CSF) receptor agonist, is used to stimulate bone marrow to produce more neutrophils in order to decrease the incidence of infection in patients undergoing chemotherapy.

About biosimilars

Biosimilar is a term used to describe officially approved subsequent versions of biopharmaceutical medicines that are made available by a different company following patent and exclusivity expiry on the original product. Biosimilars are classed as biologic medical products, which mean they contain an active drug substance that is comprised of, or derived from, a living organism.

Biosimilars are strictly regulated and need to demonstrate comparability to the previously approved reference product via a thorough development programme including quality, nonclinical and clinical data.

Remsima® (infliximab) and Truxima® (i.v. rituximab) are both registered trademarks of Celltrion, Inc. and are used under licence.

Neulasta® is a registered trademark of Amgen, Inc.

Pelmeg® is a registered trademark of Cinfa Biotech, S.L.

References:

1 Sales of Neulasta® in 2017: data from Amgen 2017 Fourth-quarter results (Global: $4,534 million. ROW: $603million). ROW sales: Available from: https://www.amgen.com/media/news-releases/2018/02/amgen-reports-fourth-quarter-and-full-year-2017-financial-results/
2 Figure based on Mundipharma data - Biosimilar savings: Truxima and Remsima net price vs originator list price x units or vials sold. Time periods are from launch, with data based on five markets for Remsima and six markets for Truxima through to year end 2017.
3Neulasta® patient information leaflet. Available from: https://www.medicines.org.uk/emc/product/6770/pil

Contact information

Mundipharma
For further information please contact:
Alison Dyson
T: +44 (0)1223 397346
alison.dyson@mundipharma.com
or email:
communications@mundipharma.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Third-Party Study Validates STATS K50 GPS’ Superior Accuracy in Measuring High-Intensity Performance18.2.2019 10:00:00Tiedote

In a recent independent study by the Technical University of Munich (TUM), STATS, the worldwide leader in sports data and intelligence, had its novel 50 Hz GPS system (STATS K50) tested against a traditional 15 Hz GPS system (GPSports SpiProX) to measure covered distance and instantaneous velocity. Both systems were simultaneously recorded and measured against a criterion reference (Laveg radar gun) during 30-metre linear sprint trials. The study, commissioned by STATS and conducted by TUM, found that STATS K-50 has a smaller bias than a traditional technology and that it is capable of quantifying high intensity activities 30% more accurately. High-intensity movements and accelerated runs over short distances are believed to be the most important variables to be tracked in sports science. STATS K50’s new approach to wearable tracking is an integrated inertial navigation system (INS)/GPS technology that combines 50 Hz GPS position and Doppler velocity measurements with inertial measurem

Electric Motor Company YASA Signs Innovation Agreement with Global Automotive Manufacturer18.2.2019 09:05:00Tiedote

YASA, the world’s leading manufacturer of axial-flux electric motors and controllers, today announced signing a long-term joint innovation agreement with a global automotive OEM. The partnership will focus on developing custom electric motor and controller solutions for the OEM’s high-performance hybrid and pure electric vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190217005021/en/ YASA axial-flux electric motor (segmented) (Photo: Business Wire) YASA’s innovative axial-flux electric motor and controller designs offer best-in-class power and torque densities and are ideally suited to both hybrid and pure electric vehicle applications. Under the agreement, YASA and the OEM will work together to leverage YASA’s technology to improve vehicle performance whilst reducing vehicle weight. This news follows YASA’s announcement last year of a new 100,000 unit capacity series production facility in Oxford, UK. In addition

Chinese Tourists Propel Alipay’s Overseas Growth during the 2019 Lunar New Year18.2.2019 07:50:00Tiedote

Alipay today announces additional statistics that reveal more about the overseas spending and mobile payment behavior of Chinese consumers during the 2019 Lunar New Year period. The data has been drawn from the 54 markets where Alipay is accepted. Combined with the preliminary findings released on Feb 11, the statistics provide a unique way to measure the pulse of China’s vibrant consumer and tourism markets. Key findings between February 4- 10 reveal: Both transaction values and volumes experienced robust growth Offline in-store transaction value surged 2.2 times year-on-year Europe dominates the top 10 countries in terms of average spend Top five countries that saw the highest growth on average spend were: Denmark (22.7 times), Spain (7.1 times), The Philippines (5 times), Belgium (4.7 times) and Switzerland (3.4 times) Asian claims nine out of top 10 countries by transaction volumes with the exception of Canada, which climbed to tenth spot due to increased adoption by local merchant

IFF Recognized by SAM’s 2019 “Industry Mover” Sustainability Award16.2.2019 00:15:00Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), was recognized for its sustainability efforts with the 2019 “Industry Mover” award from SAM, a subsidiary of RobecoSAM which specializes in providing environmental, social and governance (ESG) data, benchmarks and ratings. The recognition acknowledges the Company’s top-scoring performance in economic, social and environmental categories. “We are thrilled to receive this award from SAM,” said Andreas Fibig, IFF Chairman & CEO. “Our sustainability efforts are not only a key enabler of our overall strategy, but also a true passion here at IFF -- and we place it at the forefront of everything we do. It is deeply gratifying to have our work and our people recognized for doing the right thing for the planet.” SAM’s 2019 scoring is based on its 2018 Corporate Sustainability Assessment. Using a weighted methodology, SAM evaluates companies for criteria such as: codes of business conduct, ope

SFL: strong financial position and results in 2018, consolidating the Group’s position as a prime player15.2.2019 21:01:00Tiedote

Regulatory News: The financial statements for the year ended 31 December 2018 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 15 February 2019 at a meeting chaired by Juan José Brugera. 2018 business indicators were very robust, with further underlying growth in rental income and historically high EPRA earnings. The portfolio's appraisal value and the Company's net asset value also continued to grow, attesting to SFL’s excellent positioning. The auditors have completed their audit of the annual financial information and are in the process of issuing their report. Consolidated data (€ millions) 2018 2017 Change Rental income 193.5 195.8 -1.2% Adjusted operating profit* 162.1 164.1 -1.2% Attributable net profit 351.6 685.3 - EPRA earnings 106.7 102.4 +4.1% * Operating profit before disposal gains and losses and fair value adjustments 31/12/2018 31/12/2017 Change Attributable equity 4,010 3,763 +6.6% Consolidated portfolio value excluding transfer cost

5 Happening Cultural Destinations to Visit in 201915.2.2019 13:11:00Tiedote

Hong Kong There’s never really a sleepy year to visit Hong Kong, but 2019 is particularly ripe for visitors. Spearheaded by the dynamic entrepreneur Adrian Cheng of K11 and New World Development, the rejuvenation of Tsim Sha Tsui harbourfront is just the starting point. The city’s iconic harbourside walkway, Avenue of Stars, has just received a much-awaited makeover that’s the brainchild of Cheng and visually conceived by James Corner, the landscape architect responsible for the High Line in New York. It sees the addition of design-driven rest areas, kiosks featuring homegrown brands, hand prints from Asian film stars and interactive digital elements. Featuring Hong Kong’s first wave energy demonstrator that produces electricity for the Avenue, the place is turned into one of the most sustainable promenades in Hong Kong. This is just one part of Cheng and his company’s grander urban revitalisation plan, Victoria Dockside, a new art and design district which will fully open in the third

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme